News

The company’s Purely Soothing eye drop is used as an anti-inflammatory used to assist with symptoms of ocular irritation and/or swelling, including dry eye.

The month will help to bring awareness to eye safety in the workplace and keep eyes safe and protected on the job.

Alice Epitropoulos, MD, gives some insight into meibomian gland dysfunction (MGD), one of the most prevalent forms of dry eye.

The company’s therapeutic is a single therapy for multiple forms of age-related macular degeneration. NM3086 is a highly potent alternative pathway (AP) blocker that does not affect the classical pathway.

The voluntary recall is being issued out of an “abundance of caution” due to cracks that have developed in some of the units caps of the bottles.

Under the terms of the agreement, Grifols to have worldwide exclusive commercial rights to Selagine’s treatment upon regulatory authorization, expected in early 2029.

Under the terms of the agreement, Grifols to have worldwide exclusive commercial rights to Selagine’s treatment upon regulatory authorization, expected in early 2029.

Alice Epitropoulos, MD, gives tips on how to optimize treatment for patients with meibomian gland dysfunction (MGD).

There are now treatments available that target VEGF to prevent vessel overgrowth, and they often provide dramatic benefits at first. Unfortunately, these benefits can fade with time.

The child's changes in vision began at school and worsened over the next day to the point where he could see only outlines and shapes of objects.

Researchers recommended that patients being treated with ethambutol should be screened regularly by an ophthalmologist for the early detection of optic neuropathy.

According to researchers, the treatment with botulinum toxin is safe, fast-acting, and improves both cosmetic appearance and quality of life, and could be considered as a choice for patients not opting for surgery.

Researchers conducted a retrospective analysis of longitudinal, clinical data from patients with high myopic MNV treated with intravitreal bevacizumab.

The event will bring together patients, care partners, allied personnel, and medical professionals to speak directly with their elected officials to discuss a variety of vision and eye health issues

Cedars-Sinai investigators map changes to the retina that correspond to brain changes in the early stage, opening a path to earlier diagnosis.

Ophthalmologists could find themselves treating a growing number of young people who are applying lip balm to their eyelids, only to experience discomfort and vision issues when it gets into their eyes.

According to the company, post-hoc time-to-event analysis signals up to 59% risk reduction in rate of vision loss compared to sham treatment at 12 months. The analysis will be presented at the ARVO Annual Meeting from April 23-27 in New Orleans.

According to researchers, patients with chronic CSC treated with 1 fovea-involving, half-dose PTD application had a significant improvement in structure and function at the final follow-up and foveal atrophy did not develop in any patients.

Key is to use stem cell treatments to ensure optimal outcomes for patients.

According to James Chodosh MD, MPH, some corneal conditions may not be treatable with a transplant.

Examining the anatomy and physiology may prevent ineffective stent implantation.

At the American Glaucoma Society meeting in Austin, Texas, the company presented findings demonstrating the safety and efficacy of its FLigHT treatment.

Primary vitreoretinal lymphoma is a rare, aggressive, and potentially fatal retinal cancer that is diagnosed in approximately 300 to 600 patients in the United States per year.

Priya M. Mathews, MD, MPH discusses ophthalmology and what she wishes she knew to start her career. As well as tips for other ophthalmologists who are just starting their careers.

Stromal regeneration seems possible in patients with keratoconus.

MCO-010 has been granted orphan drug designation by the FDA for both diseases and multiple mid- to late-stage clinical trials are ongoing.

According to the company, the award advances Praetego's lead candidate, PTG-630, into preclinical proof of concept in diabetic retinopathy.

The new laser will allow surgeons to perform refractive correction on patients with myopia, with or without astigmatism using the SILK Procedure.